Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Status:
Completed
Trial end date:
2019-05-22
Target enrollment:
Participant gender:
Summary
This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to
characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor
activity of enoblituzumab administered IV on a weekly schedule for up to 96 doses
(approximately 2 years) in children and young adults with B7-H3-expressing relapsed or
refractory malignant solid tumors.